<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143972</url>
  </required_header>
  <id_info>
    <org_study_id>PIRAD-001</org_study_id>
    <nct_id>NCT03143972</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Interaction of REMI and DMED</brief_title>
  <acronym>PIRAD</acronym>
  <official_title>Pharmacodynamic Interactions Between Remifentanil and Dexmedetomidine (PIRAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MMRF Struys</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to map the pharmacokinetic / pharmacodynamic interaction between
      dexmedetomidine and remifentanil by observing changes in anesthetic depth. These changes will
      be related to drug concentrations using pharmacokinetic/pharmacodynamic (PKPD) modeling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to investigate whether the use of a combination of dexmedetomidine and
      remifentanil is clinically useful to provide anesthesia during surgical and diagnostic
      procedures and whether it could be used for anesthetic induction. Furthermore the aim is to
      gain better insights in the required dosing regimens, the inter-individual variability in
      response towards the combination and the associated side effects. Better characterization of
      this drug-drug interaction will presumably lead to more precise dosing regimens, which in
      turn, will lead to a reduction in the occurrence of oversedation, side effects and recovery
      times.

      The objective is to map the pharmacokinetic / pharmacodynamic interaction between
      dexmedetomidine and remifentanil by observing changes in anesthetic depth, measured by
      hypnotic and analgesic endpoints such as modified observer's assessment of alertness and
      sedation scale (MOAA/S), response to electrical stimuli, response to laryngoscopy and
      electroencephalogram (EEG) derived indices. These effects will be related to drug
      concentrations using pharmacokinetic/pharmacodynamic (PKPD) modeling.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All volunteers will receive 2 standardized anesthesia sessions with a washout period of at least one week between sessions. During the first session volunteers will receive dexmedetomidine, during the second session they will first receive remifentanil and afterwards the combination of drugs will be administered. Anesthetic depth will be evaluated by MOAA/S scores (see table 2), testing of tolerance to electrical stimuli and laryngoscopy. Furthermore multichannel EEG-data will be collected to get insight in the drug dependent characteristics. Measured effects will be related to drug plasma concentrations.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance of Laryngoscopy (TOL)</measure>
    <time_frame>35 - 255 minutes</time_frame>
    <description>Tolerance of a laryngoscopy (yes/no) will be tested at the end of each infusion step during both studydays, when MOAA/s is 0 / 1 and will be related to the drug concentration(s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified observer's assessment of alertness and sedation scale (MOAA/s)</measure>
    <time_frame>During anesthesia sessions day 1 and day 2</time_frame>
    <description>An hypnotic endpoint measuring depth of anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical stimulus</measure>
    <time_frame>During anesthesia sessions day 1 and day 2</time_frame>
    <description>Measuring analgesia by observing response to a standardized electrical stimulus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalogram (EEG)</measure>
    <time_frame>During anesthesia sessions day 1 and day 2</time_frame>
    <description>A multichannel electroencephalogram will be recorded</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine will be administered by effect-site TCI according to the Hannivoort model extended with an effect-site rate constant of 0.0428min-1.
A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (40 min), 3 ng/ml (50 min), 4 ng/ml (40 min), 5 ng/ml (40 min) and 8 ng/ml (70 min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil will be administered by effect-site TCI according to the Eleveld model. A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (12 min), 2 ng/ml (12 min), 3 ng/ml (12 min), 5 ng/ml (12 min) and 7 ng/ml (12 min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine-Remifentanil interaction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fixed background dose of dexmedetomidine will be given, this will be calculated after the first 5 subjects completed the dexmedetomidine only session. It will be set to 50% of the observed mean EC50TOL (Tolerance of Laryngoscopy).
Remifentanil infusion will be administered by effect site TCI with stepwise increasing targets of 0.5 - 1.0 - 1.5 - 2.0 - 2.5 - 3.0 - 4.0 ng/ml, each lasting for 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Single drug administration</description>
    <arm_group_label>Dexmedetomidine only</arm_group_label>
    <arm_group_label>Dexmedetomidine-Remifentanil interaction</arm_group_label>
    <other_name>Dexdor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Single drug administration</description>
    <arm_group_label>Remifentanil only</arm_group_label>
    <arm_group_label>Dexmedetomidine-Remifentanil interaction</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) Physical Status 1

          -  No medical history of significance

          -  No chronic use of medication, drugs, tobacco or more than 20 gr alcohol daily (oral
             contraceptives excluded).

          -  Concerning the cognitive function: Volunteers are considered to have sufficient
             cognitive reserve if they are able to read and comprehend the patient information
             form, if they can adequately answer the anamnestic questions during the screening
             process and if they are allowed to provide legitimate written informed consent.

          -  No selection will be made regarding ethnic background

          -  No exclusion criterium is present

        Exclusion Criteria:

          -  Known intolerance to dexmedetomidine or remifentanil

          -  Volunteer refusal

          -  Age &lt; 18 years or &gt;70 years

          -  Pregnancy, or currently nursing

          -  Hairstyle with dreadlocks (EEG-monitoring will not be possible)

          -  Body mass index (BMI) &lt;18 or &gt;30 kg/m2.

          -  Neurological disorder (epilepsy, the presence of a brain tumor, a history of brain
             surgery, hydrocephalic disorders, depression needing treatment with anti-depressive
             drugs, a history of brain trauma, a subarachnoidal bleeding, TIA or cerebral infarct,
             psychosis or dementia , schizophrenia, alcohol or drug abuse).

          -  Diseases involving the cardiovascular system (hypertension, coronary artery disease,
             prior acute myocardial infarction, any valvular and/or myocardial disease involving
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel MR Struys, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rob Spanjersberg</last_name>
    <phone>0031503616161</phone>
    <email>r.spanjersberg@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel MR Struys, Prof.dr.</last_name>
      <phone>031503613901</phone>
      <email>M.M.R.F.Struys@anest.umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Michel MR Struys, Prof.dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Hannivoort LN, Eleveld DJ, Proost JH, Reyntjens KM, Absalom AR, Vereecke HE, Struys MM. Development of an Optimized Pharmacokinetic Model of Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers. Anesthesiology. 2015 Aug;123(2):357-67. doi: 10.1097/ALN.0000000000000740.</citation>
    <PMID>26068206</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>MMRF Struys</investigator_full_name>
    <investigator_title>Prof. dr., head of department of anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Anonimous data might be shared with other research groups</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

